BELLUS Health is pursuing the development of BLU-5937 into a second indication, chronic pruritus. The Company plans to initiate a randomized, double-blind, placebo-controlled, parallel group design Phase 2 study to assess the efficacy, safety, and tolerability of one dose of BLU-5937 versus placebo in approximately 100 patients suffering from moderate to severe chronic pruritus associated with mild to moderate atopic dermatitis. The study is expected to begin in 2020.

Chronic pruritus, commonly known as chronic itch, is characterized as an ongoing, uncomfortable, irritating sensation that makes a person want to scratch, and persists for more than six weeks. Chronic pruritus can be debilitating and has a significant impact on quality of life. It is estimated that chronic pruritus associated with atopic dermatitis, also known as eczema, affects more than 16.9 million adults in the United States, of which three million are diagnosed, and 2.25 million are treated.

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.